Enzo Biochem Company Profile (NYSE:ENZ)

About Enzo Biochem (NYSE:ENZ)

Enzo Biochem logoEnzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical & Diagnostic Laboratories
  • Sub-Industry: N/A
  • Symbol: NYSE:ENZ
  • CUSIP: N/A
  • Web: www.enzo.com
Capitalization:
  • Market Cap: $486.05 million
  • Outstanding Shares: 46,407,000
Average Prices:
  • 50 Day Moving Avg: $11.08
  • 200 Day Moving Avg: $9.80
  • 52 Week Range: $4.88 - $12.04
P/E:
  • Trailing P/E Ratio: 14.66
  • Foreward P/E Ratio: -348.33
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $106.24 million
  • Price / Sales: 4.56
  • Book Value: $1.91 per share
  • Price / Book: 5.47
Profitability:
  • EBIDTA: ($202,000.00)
  • Net Margins: 31.57%
  • Return on Equity: -5.13%
  • Return on Assets: -4.17%
Debt:
  • Current Ratio: 5.16%
  • Quick Ratio: 4.74%
Misc:
  • Average Volume: 198,980 shs.
  • Beta: 0.92
  • Short Ratio: 2.45
 

Frequently Asked Questions for Enzo Biochem (NYSE:ENZ)

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) issued its earnings results on Wednesday, June, 8th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The company had revenue of $18.16 million for the quarter, compared to the consensus estimate of $24.50 million. Enzo Biochem had a negative return on equity of 5.13% and a net margin of 31.57%. During the same quarter in the prior year, the company earned ($0.07) EPS. View Enzo Biochem's Earnings History.

Who are some of Enzo Biochem's key competitors?

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the folowing people:

  • Barry W. Weiner, President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director
  • Elazar Rabbani Ph.D., Chairman of the Board, Chief Executive Officer, Secretary
  • James M. O'Brien, Executive Vice President - Finance
  • David C. Goldberg, Vice President - Corporate Development, General Manager of Enzo Clinical Labs
  • Dieter Schapfel M.D., Chief Medical Director
  • Bruce A. Hanna Ph.D., Director
  • Gregory M. Bortz, Independent Director
  • Dov Perlysky, Independent Director

Who owns Enzo Biochem stock?

Enzo Biochem's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Evermore Global Advisors LLC (7.66%), Renaissance Technologies LLC (4.46%), Dimensional Fund Advisors LP (4.37%), Vanguard Group Inc. (3.78%), Acadian Asset Management LLC (2.38%) and Gilder Gagnon Howe & Co. LLC (2.15%). View Institutional Ownership Trends for Enzo Biochem.

Who sold Enzo Biochem stock? Who is selling Enzo Biochem stock?

Enzo Biochem's stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, GSA Capital Partners LLP, Wells Fargo & Company MN, Acadian Asset Management LLC, Nationwide Fund Advisors, Kopp Investment Advisors LLC, Eagle Global Advisors LLC and Arrowstreet Capital Limited Partnership. View Insider Buying and Selling for Enzo Biochem.

Who bought Enzo Biochem stock? Who is buying Enzo Biochem stock?

Enzo Biochem's stock was bought by a variety of institutional investors in the last quarter, including Evermore Global Advisors LLC, Dimensional Fund Advisors LP, Gilder Gagnon Howe & Co. LLC, TIAA CREF Investment Management LLC, Mckinley Capital Management LLC Delaware, Alliancebernstein L.P., Marathon Capital Management and Abner Herrman & Brock LLC. View Insider Buying and Selling for Enzo Biochem.

How do I buy Enzo Biochem stock?

Shares of Enzo Biochem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of Enzo Biochem stock can currently be purchased for approximately $10.45.


MarketBeat Community Rating for Enzo Biochem (NYSE ENZ)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  129
MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Enzo Biochem (NYSE:ENZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Enzo Biochem (NYSE:ENZ)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/9/2016Dawson JamesReiterated RatingBuyN/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Enzo Biochem (NYSE:ENZ)
Earnings by Quarter for Enzo Biochem (NYSE:ENZ)
Earnings History by Quarter for Enzo Biochem (NYSE ENZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017Q2 2017($0.04)($0.02)$26.10 million$26.26 millionViewN/AView Earnings Details
12/8/2016Q117($0.05)($0.03)$25.90 million$26.28 millionViewN/AView Earnings Details
10/13/2016Q416($0.06)($0.04)$26.00 million$26.60 millionViewN/AView Earnings Details
6/8/2016Q316($0.06)($0.04)$24.50 million$18.16 millionViewN/AView Earnings Details
3/9/2016Q216($0.06)($0.07)$24.43 million$24.60 millionViewN/AView Earnings Details
12/7/2015Q116($0.05)($0.05)$25.00 million$25.18 millionViewN/AView Earnings Details
10/13/2015Q415($0.06)($0.06)$24.60 million$25.70 millionViewListenView Earnings Details
6/9/2015Q315($0.06)($0.07)$24.40 million$23.99 millionViewN/AView Earnings Details
3/12/2015Q215($0.09)($0.09)$24.20 million$23.09 millionViewN/AView Earnings Details
12/9/2014Q114($0.08)($0.08)$24.50 million$24.82 millionViewListenView Earnings Details
10/9/2014Q4 2014($0.07)($0.06)$23.60 million$24.91 millionViewListenView Earnings Details
6/9/2014Q314($0.09)($0.05)$22.80 million$24.00 millionViewN/AView Earnings Details
3/11/2014Q2($0.08)($0.09)$22.00 million$22.93 millionViewListenView Earnings Details
12/11/2013Q1($0.06)($0.07)ViewListenView Earnings Details
10/16/2013Q413($0.08)$22.00 million$23.30 millionViewListenView Earnings Details
6/10/2013Q3 2013($0.15)$22.20 million$22.60 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enzo Biochem (NYSE:ENZ)
Current Year EPS Consensus Estimate: $-0.07 EPS
Next Year EPS Consensus Estimate: $-0.03 EPS

Dividends

Dividend History for Enzo Biochem (NYSE:ENZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enzo Biochem (NYSE:ENZ)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Enzo Biochem (NYSE:ENZ)
Latest Headlines for Enzo Biochem (NYSE:ENZ)
Source:
DateHeadline
businesswire.com logoEnzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8 ... - Business Wire (press release)
www.businesswire.com - September 23 at 3:27 AM
finance.yahoo.com logoEnzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8:30 AM E.T.
finance.yahoo.com - September 22 at 5:23 PM
thestreet.com logoEnzo Biochem Is Now Oversold (ENZ)
www.thestreet.com - September 19 at 6:20 PM
finance.yahoo.com logoEnzo Biochem, Inc. breached its 50 day moving average in a Bullish Manner : ENZ-US : September 1, 2017
finance.yahoo.com - September 1 at 6:40 PM
finance.yahoo.com logoEnzo Biochem, Inc. – Value Analysis (NYSE:ENZ) : August 25, 2017
finance.yahoo.com - August 25 at 7:59 PM
finance.yahoo.com logoEnzo Biochem, Inc. breached its 50 day moving average in a Bearish Manner : ENZ-US : August 17, 2017
finance.yahoo.com - August 17 at 7:31 PM
reuters.com logoBRIEF-Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories
www.reuters.com - August 16 at 9:03 PM
americanbankingnews.com logoEnzo Biochem, Inc. (ENZ) Downgraded by Zacks Investment Research
www.americanbankingnews.com - August 15 at 6:08 PM
finance.yahoo.com logoGeron's (GERN) Imetelstat Progressing Well, Setbacks Concern
finance.yahoo.com - August 14 at 6:42 PM
nasdaq.com logoThe Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss
www.nasdaq.com - August 11 at 12:38 AM
finance.yahoo.com logoPerrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised
finance.yahoo.com - August 10 at 7:35 PM
finance.yahoo.com logoCatalyst (CPRX) Posts Narrower than Expected Loss in Q2
finance.yahoo.com - August 10 at 7:35 PM
finance.yahoo.com logoOrexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
finance.yahoo.com - August 9 at 6:28 PM
finance.yahoo.com logoJazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
finance.yahoo.com - August 9 at 6:28 PM
finance.yahoo.com logoEpizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2
finance.yahoo.com - August 7 at 6:34 PM
finance.yahoo.com logoJuno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass
finance.yahoo.com - August 4 at 6:33 PM
finance.yahoo.com logoStrongbridge Biopharma (SBBP) Rises: Stock Moves 17% Higher
finance.yahoo.com - August 1 at 6:57 PM
finance.yahoo.com logoDr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise
finance.yahoo.com - July 31 at 6:03 PM
americanbankingnews.com logoEnzo Biochem, Inc. (ENZ) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 29 at 5:59 PM
marketwatch.com logoImmunoprotein Diagnostic Testing Market Worth $10.3 Billion by 2025: Grand View Research, Inc.
www.marketwatch.com - July 27 at 11:54 PM
nasdaq.com logoBristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View - Nasdaq
www.nasdaq.com - July 27 at 6:51 PM
finance.yahoo.com logoBristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View
finance.yahoo.com - July 27 at 6:51 PM
finance.yahoo.com logoGlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance
finance.yahoo.com - July 27 at 6:51 PM
finance.yahoo.com logoGalapagos (GLPG) Looks Good: Stock Adds 6.2% in Session
finance.yahoo.com - July 21 at 8:14 PM
finance.yahoo.com logoValeant (VRX) To Sell Obagi for $190 Million to Lower Debt
finance.yahoo.com - July 19 at 4:43 PM
finance.yahoo.com logoPerrigo Company Gets FDA Approval for Generic Topical Gel
finance.yahoo.com - July 18 at 7:51 PM
nasdaq.com logoCan Enzo Biochem (ENZ) Run Higher on Strong Earnings Estimate ... - Nasdaq
www.nasdaq.com - July 14 at 4:10 PM
finance.yahoo.com logoCan Enzo Biochem (ENZ) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - July 14 at 4:10 PM
finance.yahoo.com logoGilead (GILD) Application for HIV Drug Validated in EU
finance.yahoo.com - July 14 at 4:10 PM
finance.yahoo.com logo5 Stocks with Recent Price Strength to Enhance Your Returns
finance.yahoo.com - July 13 at 7:40 PM
finance.yahoo.com logoBioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug
finance.yahoo.com - July 13 at 7:40 PM
nasdaq.com logoMallinckrodt to Pay $35M for Controlled Substances Probe - Nasdaq
www.nasdaq.com - July 13 at 12:07 AM
finance.yahoo.com logoRoche (RHHBY) Announces Positive Data on Hemophilia A Drug
finance.yahoo.com - July 11 at 7:28 PM
seekingalpha.com logoEnzo Biochem Rounds The Corner
seekingalpha.com - July 10 at 6:12 PM
finance.yahoo.com logoETFs with exposure to Enzo Biochem, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 6:12 PM
americanbankingnews.com logoHead to Head Review: Enzo Biochem (NYSE:ENZ) vs. NeoGenomics (NEO)
www.americanbankingnews.com - July 1 at 4:04 PM
americanbankingnews.com logoEnzo Biochem (ENZ) and RadNet (RDNT) Financial Comparison
www.americanbankingnews.com - July 1 at 12:14 AM
finance.yahoo.com logoEnzo Biochem Reports Delaware Court Ruling
finance.yahoo.com - June 29 at 7:51 PM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Enzo Biochem (ENZ)
finance.yahoo.com - June 22 at 10:01 AM
finance.yahoo.com logoLooking for a Top Momentum Stock? 3 Reasons Why Enzo Biochem (ENZ) is a Great Choice
finance.yahoo.com - June 21 at 6:33 PM
americanbankingnews.com logoEnzo Biochem, Inc. (ENZ) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - June 20 at 10:30 PM
finance.yahoo.com logoETFs with exposure to Enzo Biochem, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 7:37 PM
americanbankingnews.com logoZacks: Enzo Biochem, Inc. (ENZ) Given $8.00 Average Target Price by Analysts
www.americanbankingnews.com - June 15 at 4:20 PM
investopedia.com logoTop 5 Biotech Stocks as of June 2017 (JAZZ, ENZ)
www.investopedia.com - June 14 at 11:07 PM
finance.yahoo.com logoEnzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q3, 2017 By the Numbers : June 12, 2017
finance.yahoo.com - June 12 at 5:53 PM
finance.yahoo.com logoEnzo Biochem, Inc.: Strong price momentum but will it sustain?
finance.yahoo.com - June 12 at 5:53 PM
finance.yahoo.com logoEdited Transcript of ENZ earnings conference call or presentation 9-Jun-17 12:30pm GMT
finance.yahoo.com - June 9 at 10:29 PM
nasdaq.com logoMid-Afternoon Market Update: NASDAQ Down 2.5%; DuPont Fabros Shares Spike Higher
www.nasdaq.com - June 9 at 5:27 PM
seekingalpha.com logoEnzo Biochem's (ENZ) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - June 9 at 5:27 PM
finance.yahoo.com logoETFs with exposure to Enzo Biochem, Inc. : June 9, 2017
finance.yahoo.com - June 9 at 5:27 PM

Social

Chart

Enzo Biochem (ENZ) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff